UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049086
Receipt number R000055894
Scientific Title Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database
Date of disclosure of the study information 2022/10/03
Last modified on 2023/10/03 07:02:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Acronym

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Scientific Title

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Scientific Title:Acronym

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Region

Japan


Condition

Condition

heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate renal safety of analgesics in patients with heart failure

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

- Proportion of analgesics use in heart failure patients
- Categories at baseline and sequential changes of renal function after administration of analgesics in patients with heart failure (eGFR or serum creatinine level)

Key secondary outcomes

- Proportion and frequency of combination therapy other than analgesics (especially focusing on Triple Warmy Drugs) by category
- For analgesics, proportion of concomitant use, daily and cumulative dose distribution, and proportion of single use
- Distribution of registered comorbidities
- Sequential changes of biomarker [index] in patients with heart failure from baseline (BNP or NT-proBNP) (BNP or NT-proBNP)
- Incidence proportion of heart failure exacerbation events (hospitalization due to heart failure, administration of intravenous diuretics, and increased dose of oral diuretic)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with heart failure (ICD-10 code: I50x) and BNP or NT-proBNP measurements

Key exclusion criteria

cancer, surgery, pregnancy

Target sample size

0


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Sato

Organization

Kawaguchi Cardiovascular and Respiratory Hospital

Division name

cardiology

Zip code

333-0842

Address

1-51 Maekawa 1-Chome, Kawaguchi-city, Saitama, Japan

TEL

048-264-5533

Email

nms-ns@nms.ac.jp


Public contact

Name of contact person

1st name Toshi
Middle name
Last name Takano

Organization

AYUMI PHARMACEUTICAL CO., LTD

Division name

Medical Affairs Div.

Zip code

104-0061

Address

12-15 Ginza 4-Chome, Chuo-ku, Tokyo, Japan

TEL

0362643530

Homepage URL


Email

toshio.takano@ayumi-pharma.com


Sponsor or person

Institute

Kawaguchi Cardiovascular and Respiratory Hospita

Institute

Department

Personal name



Funding Source

Organization

AYUMI PHARMACEUTICAL CO., LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kurashiki Central Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kurashiki Central Hospital Ethics Committee

Address

Miwa 1-1-1, Kurashiki, Okayama

Tel

086-422-0210

Email

kenkyu@kchnet.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 09 Month 20 Day

Date of IRB

2022 Year 09 Month 27 Day

Anticipated trial start date

2022 Year 10 Month 03 Day

Last follow-up date

2024 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

A descriptive study using anonymously processed information in a Japanese healthcare database.
No formal sample size calculation was conducted for the present study due to the nature of database study.


Management information

Registered date

2022 Year 10 Month 01 Day

Last modified on

2023 Year 10 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055894


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name